{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:02:09Z","timestamp":1762430529290},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":400,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:p>This study investigated the effect of eslicarbazepine acetate (ESL) on cardiac repolarization in healthy adult volunteers. A randomized, placebo\/active\u2010controlled, 4\u2010period crossover study was conducted in 67 participants. In 3 periods, participants received once\u2010daily doses of ESL 1200 mg, ESL 2400 mg, and placebo for 5 days; in 1 period, participants received placebo on days 1 to 4 and a 400\u2010mg moxifloxacin single dose on day 5. In each period, 24\u2010hour 12\u2010lead Holter monitoring was performed on days \u2212;1 (baseline) and 5. There was no clinically relevant effect of ESL 1200 mg and 2400 mg versus placebo on cardiac depolarization or repolarization as measured by the QRS or QTc intervals, respectively. Mean PR interval increased following ESL 1200 mg and 2400 mg, but there was no participant with a PR interval above the upper limit of the normal range (200 ms). The upper bound of the 95% confidence interval for the placebo\u2010corrected change from baseline of the individually corrected QT interval (QTcI) following administration of ESL 1200 mg and ESL 2400 mg was &lt;10 ms at every time point. Moxifloxacin caused an increase in QTcI above the 10\u2010ms threshold for clinical significance at several time points, demonstrating assay sensitivity. It is concluded that administration of ESL 1200 mg and ESL 2400 mg did not induce a clinically significant prolongation of the QTcI interval.<\/jats:p>","DOI":"10.1177\/0091270010391789","type":"journal-article","created":{"date-parts":[[2011,3,18]],"date-time":"2011-03-18T00:16:00Z","timestamp":1300407360000},"page":"222-233","source":"Crossref","is-referenced-by-count":22,"title":["Evaluation of Eslicarbazepine Acetate on Cardiac Repolarization in a Thorough QT\/QTc Study"],"prefix":"10.1002","volume":"52","author":[{"given":"Manuel","family":"Vaz\u2010Da\u2010Silva","sequence":"first","affiliation":[]},{"given":"Teresa","family":"Nunes","sequence":"additional","affiliation":[]},{"given":"Luis","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Maria J.","family":"Gutierrez","sequence":"additional","affiliation":[]},{"given":"Jeffrey S.","family":"Litwin","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcio","family":"Soares\u2010Da\u2010Silva","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2010.01.014"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.00984.x"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01946.x"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2009.01218.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/9781444316667.ch38"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-007-0414-1"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005279364"},{"key":"e_1_2_5_9_2","first-page":"196","article-title":"Pharmacokinetics of eslicarbazepine acetate at steady\u2010state in adults with epilepsy","volume":"50","author":"Perucca E","year":"2008","journal-title":"Epilepsia"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/0126839-200809060-00007"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00126839-200506040-00002"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02660.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm980627g"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.51.5.1270"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01082.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00126839-200304050-00001"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004267591"},{"key":"e_1_2_5_18_2","first-page":"A458","article-title":"An investigation of the effect of eslicarbazepine acetate on cardiac repolarization: a pooled analysis of over\u2010read electrocardiograms from three double\u2010blind phase III clinical studies","volume":"74","author":"Versavel M","year":"2010","journal-title":"Neurology"},{"key":"e_1_2_5_19_2","first-page":"61134","article-title":"Clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non\u2010antiarrhythmic drugs","volume":"70","year":"2005","journal-title":"Fed Regist"},{"key":"e_1_2_5_20_2","first-page":"61134","article-title":"ICH E14 guidance: the QT\/QTc interval prolongation and proarrhythmic potential for non\u2010antiarrhythmic drugs","volume":"70","year":"2005","journal-title":"Fed Regist"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.5414\/CPP46119"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.111482"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1086\/323015"},{"key":"e_1_2_5_24_2","volume-title":"CHMP Assessment Report for Exalief 2009","author":"Committee for Medicinal Products for Human Use (CHMP)","year":"2009"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a015357"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270010391789","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270010391789","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T21:00:05Z","timestamp":1698699605000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270010391789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.1177\/0091270010391789"],"URL":"https:\/\/doi.org\/10.1177\/0091270010391789","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}